In vivo and non-invasive measurement of cytokine release in a model of acute and local skin inflammatio

Completed

• Conditions: cytokines; inflammatory molecules; 10014982

• Registration Number: NL-OMON43271
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Age between 18 and 65 years;
Must be willing to give a written informed consent;
Must have skin type I, II or III (Fitzpatrick scale).

Exclusion Criteria

Diagnosis of histamine hypersensitivity;
Predisposition to respond allergic (including diagnosis of allergy to silver or to other device-related material);
Presence of cardiac pacemakers or other implanted electric devices;
Pregnancy or lactation;
Atopic predisposition (i.e. history of allergic rhinitis or allergic conjunctivitis, atopic or contact dermatitis, hay fever, asthma);
Any (skin) disease, including possible lesions found during screening;
Skin type IV, V, VI (Fitzpatrick scale);
Use of immunosuppressive drugs (NSAIDs; biologicals; topical or systemic corticosteroids);
Use of antihistamines drugs;
Use of medication for hypertension with airway constricting activity (e.g. beta blockers);
Excessive sun exposure or tanning at the moment of screening.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoints are the levels of cytokines at baseline and at<br /><br>different time points following local skin inflammation elicited by histamine<br /><br>iontophoresis. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>